The Complement system is an intriguing potential pathway for treating ALS. It’s an essential part of the immune system – and many researchers believe its dysregulation could play a role in some cases of ALS. A class of drugs known as “complement inhibitors” seek to treat ALS by targeting certain proteins that are part of the complement system, also known as the complement cascade.
On Endpoints, we’ve previously discussed one complement inhibitor that’s in trials as a treatment for ALS, Alexion’s Ravulizimab. Today, we’re looking at another potential treatment – Pegcetacoplan, a C3 inhibitor that’s currently in a phase 2 trial for ALS sponsored by the company Apellis.
The Complement system is an intriguing potential pathway for treating ALS. It’s an essential part of the immune system – and many researchers believe its dysregulation could play a role in some cases of ALS. A class of drugs known as “complement inhibitors” seek to treat ALS by targeting certain proteins that are part of the complement system, also known as the complement cascade.
On Endpoints, we’ve previously discussed one complement inhibitor that’s in trials as a treatment for ALS, Alexion’s Ravulizimab. Today, we’re looking at another potential treatment – Pegcetacoplan, a C3 inhibitor that’s currently in a phase 2 trial for ALS sponsored by the company Apellis.
